Leukaemia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People newly diagnosed with T-cell or B-cell precursor acute lymphoblastic leukaemia (ALL), confirmed by an approved laboratory at a participating cancer or blood disease centre.
• People who are between 0 and 45 years old (up to the day before their 46th birthday) at the time of diagnosis — with an exception for very young infants with a specific genetic type of ALL (see below).
• People with a specific type of B-cell precursor ALL that tests negative for surface immunoglobulin and has a particular gene change called IG::MYC, unless a second gene change (BCL2/6) is also present — or T-cell ALL patients with a MYC gene change.
• People who are diagnosed and treated at a centre that is officially participating in this trial.
• People who live permanently in one of the countries participating in the trial, or who intend to stay — for example, people applying for asylum. People visiting as tourists are not included, though returning long-term residents or people planning to stay for the full treatment may be considered if no treatment has yet been given and tests are repeated at a participating centre.
• People (or their parents or legal guardians) who have signed the required consent forms, following the rules of their country.
• Women who could become pregnant must have a negative pregnancy test within 2 weeks before treatment starts.

Who may not be able to join:

• Infants under 365 days old who have a specific genetic type of ALL involving the KMT2A gene — these patients may be directed to a different trial designed for this group.
• People who are 46 years old or older at the time of diagnosis.
• People who have previously had a cancer diagnosis before this ALL diagnosis.
• People whose ALL has come back after earlier treatment (relapse).
• People with a type called mature B-ALL (which tests positive for surface immunoglobulin), or those with the IG::MYC gene change alongside a BCL2/6 gene change.
• People with a type of ALL involving a specific chromosome change known as Philadelphia chromosome positive (Ph+) ALL — these patients may be directed to a different, more appropriate trial.
• People already known to have certain inherited conditions that make ALL more likely (such as Li-Fraumeni syndrome or a germline ETV6 mutation) — though Down syndrome is an exception and does not exclude someone. Note: testing for these conditions is not required to join, and patients in whom a new inherited change is discovered during the study may remain in the trial.
• People who received steroid medicines (above a specific dose) for more than one week, or any chemotherapy, in the four weeks before diagnosis.
• People who have a pre-existing health condition that would prevent them from safely receiving the treatments used in this trial (confirm with trial site).
• People with any other condition that the treating doctor believes would make it unsafe or unsuitable for them to participate in the study.
• Women who are pregnant at the time of diagnosis.
• Women who could become pregnant, or men who could father a child, who are sexually active and are not willing to use reliable contraception throughout treatment.
• Women who are currently breastfeeding.
• Cases where important information required at the time of diagnosis registration is missing (this is determined in discussion with the trial leadership).

Important: Always verify eligibility with the trial site directly before applying.